|

Rezvilutamide Clinical Trials

8 actively recruiting trials across 1 location

▲ +1 trial since May 2026

Also known as: ADT, Ariane, SHR3680

Pipeline

Phase 2: 5Phase 3: 2Phase 1/2: 1

Top Sponsors

  • The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School3
  • The First Affiliated Hospital with Nanjing Medical University1
  • The First Affiliated Hospital of Xiamen University1
  • Peking University First Hospital1
  • Jiangsu HengRui Medicine Co., Ltd.1

Indications

  • Cancer8
  • Prostate Cancer3
  • Biochemical Recurrence2
  • Locally Advanced Prostate Cancer2
  • Salivary Gland Neoplasm Duct1

Other7 trials

A Clinical Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate Cancer
Phase 1/2
Adjuvant Rezvilutamide in Combination With Androgen Deprivation Therapy in Androgen Receptor-positive, High-risk Salivary Duct Carcinoma
Phase 2
Comparing the Efficacy and Safety of Rezvilutamide+ADT+Docetaxel Versus Rezvilutamide +ADT in the mHSPC
Phase 3
Genomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO)
Phase 2
Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer
Phase 2
Rezvilutamide in Patients With Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
Phase 2
Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
Phase 2

Dothan, Alabama1 trial

AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)

Research Site

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.